{"id":2784,"date":"2026-07-25T23:46:57","date_gmt":"2026-07-25T22:46:57","guid":{"rendered":"https:\/\/seamlessbio.de\/?page_id=2784"},"modified":"2026-07-25T23:46:59","modified_gmt":"2026-07-25T22:46:59","slug":"human-serum-vs-hpl-vs-fbs","status":"publish","type":"page","link":"https:\/\/seamlessbio.de\/de\/human-serum-vs-hpl-vs-fbs\/","title":{"rendered":"Guide Human Serum vs. HPL vs. FBS"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"2784\" class=\"elementor elementor-2784\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-53f5bc8 e-con e-atomic-element e-flexbox-base e-74e4dbd\" data-id=\"53f5bc8\" data-element_type=\"e-flexbox\" data-e-type=\"e-flexbox\" data-interaction-id=\"53f5bc8\">\n    \t\t<div class=\"elementor-element elementor-element-75b755e elementor-widget elementor-widget-html\" data-id=\"75b755e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t\t<style>\n.sb-cmp{--t:#18b7b2;--th:#139b97;--d:#202020;--g:#5b6b71;--bg:#f1faf9;--ln:#e2eceb;font-family:-apple-system,BlinkMacSystemFont,\"Segoe UI\",Roboto,Helvetica,Arial,sans-serif;color:var(--d);line-height:1.7;max-width:1140px;margin:0 auto;padding:40px 20px 80px;}\n.sb-cmp *{box-sizing:border-box;}\n.sb-cmp .bc{font-size:13px;color:var(--g);margin-bottom:24px;}\n.sb-cmp .bc a{color:var(--g);text-decoration:none;}\n.sb-cmp .bc a:hover{color:var(--t);}\n.sb-cmp .bc span{margin:0 8px;}\n.sb-cmp .hero{background:linear-gradient(135deg,#e4f6f5 0%,#f4fbfb 55%,#ffffff 100%);border:1px solid rgba(24,183,178,.18);border-radius:26px;padding:52px 48px;margin-bottom:16px;}\n.sb-cmp .ey{display:inline-block;font-size:11px;font-weight:800;letter-spacing:.09em;text-transform:uppercase;color:var(--th);margin-bottom:16px;}\n.sb-cmp h1{font-size:37px;line-height:1.18;font-weight:800;margin:0 0 18px;letter-spacing:-.5px;}\n.sb-cmp .sub{font-size:18px;color:var(--g);margin:0 0 28px;max-width:780px;}\n.sb-cmp .hbtn{display:flex;flex-wrap:wrap;gap:14px;}\n.sb-cmp .btn{display:inline-flex;align-items:center;justify-content:center;min-height:50px;padding:0 30px;border-radius:999px;background:var(--t);color:#fff!important;text-decoration:none!important;font-size:14px;font-weight:800;text-transform:uppercase;letter-spacing:.04em;transition:.2s;}\n.sb-cmp .btn:hover{background:var(--th);}\n.sb-cmp .btn-o{display:inline-flex;align-items:center;justify-content:center;min-height:50px;padding:0 30px;border-radius:999px;background:#fff;border:2px solid var(--t);color:var(--t)!important;text-decoration:none!important;font-size:14px;font-weight:800;text-transform:uppercase;letter-spacing:.04em;transition:.2s;}\n.sb-cmp .btn-o:hover{background:var(--t);color:#fff!important;}\n.sb-cmp .answer{background:var(--bg);border-left:5px solid var(--t);border-radius:0 16px 16px 0;padding:26px 30px;margin:0 0 44px;font-size:17px;}\n.sb-cmp .answer strong.lb{display:block;font-size:13px;text-transform:uppercase;letter-spacing:.06em;color:var(--th);margin-bottom:8px;}\n.sb-cmp h2{font-size:27px;font-weight:800;margin:54px 0 8px;line-height:1.25;}\n.sb-cmp h3{font-size:19px;font-weight:700;margin:30px 0 10px;}\n.sb-cmp .lede{font-size:17px;font-weight:600;margin:0 0 18px;}\n.sb-cmp p{margin:0 0 16px;}\n.sb-cmp a{color:var(--t);}\n.sb-cmp ul,.sb-cmp ol{margin:0 0 16px;padding-left:22px;}\n.sb-cmp li{margin-bottom:9px;}\n.sb-cmp .tw{overflow-x:auto;-webkit-overflow-scrolling:touch;margin:26px 0;}\n.sb-cmp table{width:100%;min-width:660px;border-collapse:collapse;font-size:15px;}\n.sb-cmp th{background:var(--t);color:#fff;text-align:left;padding:13px 15px;font-weight:700;font-size:14px;}\n.sb-cmp td{padding:13px 15px;border-bottom:1px solid var(--ln);vertical-align:top;}\n.sb-cmp tr:last-child td{border-bottom:none;}\n.sb-cmp .three{display:grid;grid-template-columns:repeat(3,1fr);gap:18px;margin:28px 0;}\n.sb-cmp .card{background:#fff;border:1px solid var(--ln);border-top:4px solid var(--t);border-radius:0 0 18px 18px;padding:26px;}\n.sb-cmp .card h3{margin-top:0;font-size:18px;}\n.sb-cmp .card p{font-size:15px;color:var(--g);margin-bottom:0;}\n.sb-cmp .note{background:var(--bg);border-left:4px solid var(--t);border-radius:0 12px 12px 0;padding:20px 24px;margin:26px 0;font-size:15px;}\n.sb-cmp .faq{background:var(--bg);border-radius:20px;padding:36px;margin:54px 0;}\n.sb-cmp .faq h2{margin-top:0;}\n.sb-cmp .fq{font-weight:700;font-size:17px;margin:26px 0 6px;}\n.sb-cmp .faq .fq:first-of-type{margin-top:18px;}\n.sb-cmp .rel{border-top:2px solid var(--ln);padding-top:30px;margin-top:50px;}\n.sb-cmp .rel h2{margin-top:0;font-size:21px;}\n.sb-cmp .rg{display:grid;grid-template-columns:repeat(3,1fr);gap:12px;}\n.sb-cmp .rg a{display:block;padding:15px 18px;background:var(--bg);border-radius:12px;text-decoration:none;font-weight:600;font-size:15px;transition:.2s;}\n.sb-cmp .rg a:hover{background:var(--t);color:#fff;}\n.sb-cmp .cta{background:linear-gradient(135deg,#e4f6f5 0%,#f4fbfb 100%);border:1px solid rgba(24,183,178,.18);border-radius:26px;padding:48px 40px;text-align:center;margin-top:50px;}\n.sb-cmp .cta h2{margin:0 0 12px;}\n.sb-cmp .cta p{color:var(--g);margin:0 auto 26px;max-width:640px;}\n@media(max-width:900px){.sb-cmp .three,.sb-cmp .rg{grid-template-columns:1fr;}}\n@media(max-width:700px){.sb-cmp{padding:26px 14px 56px;}.sb-cmp .hero{padding:32px 24px;border-radius:18px;}.sb-cmp h1{font-size:26px;}.sb-cmp h2{font-size:22px;}.sb-cmp .sub{font-size:16px;}.sb-cmp .btn,.sb-cmp .btn-o{width:100%;}.sb-cmp .faq,.sb-cmp .cta{padding:26px 20px;}.sb-cmp .card{padding:22px;}}\n<\/style>\n\n<div class=\"sb-cmp\">\n\n  <div class=\"bc\">\n    <a href=\"https:\/\/seamlessbio.de\/de\/\">Startseite<\/a><span>\/<\/span>\n    <a href=\"https:\/\/seamlessbio.de\/de\/ressourcen\/\">Ressourcen<\/a><span>\/<\/span>\n    <strong>Humanes Serum vs. hPL vs. FBS<\/strong>\n  <\/div>\n\n  <div class=\"hero\">\n    <span class=\"ey\">Cell Culture Supplements \u00b7 MSC &amp; ATMP<\/span>\n    <h1>Human Serum vs. hPL vs. FBS \u2014 Which Supplement for MSC and ATMP Manufacturing?<\/h1>\n    <p class=\"sub\">Three supplements, three different problems solved. This comparison covers what each one does well, where each fails, and what a switch actually costs you in validation time.<\/p>\n    <div class=\"hbtn\">\n      <a class=\"btn\" href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\">Request samples of all three<\/a>\n      <a class=\"btn-o\" href=\"https:\/\/seamlessbio.de\/de\/human-serum-guide\/\">Human serum selection guide<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"answer\">\n    <strong class=\"lb\">In short<\/strong>\n    F\u00fcr <strong>MSC expansion in a clinical or ATMP context, hPL<\/strong> is now the default \u2014 highest growth factor content, human origin, fastest proliferation. For <strong>primary human cells and immunology work, human serum Type AB<\/strong>. <strong>FBS<\/strong> remains reasonable for established cell lines and research, but is increasingly hard to defend in anything heading toward the clinic.\n  <\/div>\n\n  <h2>What each one actually is<\/h2>\n\n  <div class=\"three\">\n    <div class=\"card\">\n      <h3>FBS \u2014 Fetal Bovine Serum<\/h3>\n      <p>Bovine origin, collected from foetal calf blood. Rich in growth factors, low in immunoglobulins, and the reference supplement for cell culture for over fifty years. Xenogeneic by definition.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <h3>HS \u2014 Human Serum<\/h3>\n      <p>From human whole blood or plasma. Removes the species barrier. Type AB avoids isoagglutinins; <a href=\"https:\/\/seamlessbio.de\/de\/human-serum-off-the-clot-vs-plasma-derived\/\">off-the-clot<\/a> preserves the platelet growth factor profile.<\/p>\n    <\/div>\n    <div class=\"card\">\n      <h3>hPL \u2014 Human Platelet Lysate<\/h3>\n      <p>Produced by lysing platelet concentrates, usually through freeze-thaw cycles. The \u03b1-granules rupture and release their contents, giving a supplement far richer in growth factors than either serum.<\/p>\n    <\/div>\n  <\/div>\n\n  <h2>Side by side<\/h2>\n\n  <div class=\"tw\">\n    <table>\n      <thead><tr><th><\/th><th>FBS<\/th><th>Human Serum (AB)<\/th><th>hPL<\/th><\/tr><\/thead>\n      <tbody>\n        <tr><td><strong>Herkunft<\/strong><\/td><td>Bovine \u2014 xenogeneic<\/td><td>Human<\/td><td>Human<\/td><\/tr>\n        <tr><td><strong>Gehalt an Wachstumsfaktoren<\/strong><\/td><td>Moderate to high<\/td><td>M\u00e4\u00dfig<\/td><td>Hoch<\/td><\/tr>\n        <tr><td><strong>MSC proliferation<\/strong><\/td><td>Quelle<\/td><td>Comparable to slower<\/td><td>Markedly faster<\/td><\/tr>\n        <tr><td><strong>Xeno-free claim<\/strong><\/td><td>Nein<\/td><td>Ja<\/td><td>Yes, if heparin-free<\/td><\/tr>\n        <tr><td><strong>ATMP acceptance<\/strong><\/td><td>Under regulatory pressure<\/td><td>Accepted<\/td><td>Established practice<\/td><\/tr>\n        <tr><td><strong>Handling issues<\/strong><\/td><td>None specific<\/td><td>None specific<\/td><td>Fibrinogen \u2014 gel formation<\/td><\/tr>\n        <tr><td><strong>Batch variability<\/strong><\/td><td>High, seasonal and regional<\/td><td>Donor dependent<\/td><td>Reduced by large pools<\/td><\/tr>\n        <tr><td><strong>Typical use level<\/strong><\/td><td>10 %<\/td><td>5\u201310 %<\/td><td>Often 5 % or less<\/td><\/tr>\n        <tr><td><strong>Supply<\/strong><\/td><td>Volatile, price sensitive<\/td><td>Limited, especially AB off-the-clot<\/td><td>Gut<\/td><\/tr>\n        <tr><td><strong>Ethical profile<\/strong><\/td><td>Contested \u2014 3Rs pressure<\/td><td>Donor consent based<\/td><td>Uses expired platelet units<\/td><\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <h2>Why FBS is losing ground in clinical work<\/h2>\n\n  <p class=\"lede\">Not because it performs badly. Because it is bovine.<\/p>\n\n  <p>Four arguments come up in every ATMP review, and none of them is about culture performance:<\/p>\n\n  <ul>\n    <li><strong>Immunogenicity.<\/strong> Cells cultured in FBS internalise bovine proteins. When those cells are administered to a patient, the bovine material comes with them. Immune responses to bovine serum albumin have been documented in cell therapy recipients.<\/li>\n    <li><strong>Adventitious agents.<\/strong> TSE and viral risk is managed through sourcing and testing, but it cannot be eliminated by design the way it can with a human-origin product.<\/li>\n    <li><strong>Batch variability.<\/strong> Composition varies with herd, region and season. For a process that must stay comparable over years, that is a validation burden rather than a nuisance.<\/li>\n    <li><strong>Supply and price.<\/strong> The FBS market has repeatedly shown sharp price movements and constrained availability. A clinical programme cannot absorb that.<\/li>\n  <\/ul>\n\n  <p>For research on established cell lines none of this applies with force, and FBS remains the pragmatic choice. Our <a href=\"https:\/\/seamlessbio.de\/de\/vergleich-der-herkunft-von-fbs\/\">FBS origin comparison<\/a> covers the sourcing question separately.<\/p>\n\n  <h2>Why hPL outperforms both for MSC<\/h2>\n\n  <p class=\"lede\">The growth factors are concentrated by design, not by accident.<\/p>\n\n  <p>In serum, platelet growth factors end up in the product as a by-product of clotting \u2014 however much the platelets happened to release. In hPL, platelet concentrates are lysed deliberately, so the \u03b1-granule contents are the product rather than a residue.<\/p>\n\n  <p>The practical result for mesenchymal stromal cells is faster population doubling, more doublings before senescence, and \u2014 importantly for ATMP \u2014 retained immunophenotype and differentiation potential. That combination is why hPL has moved from an alternative to the default in clinical MSC manufacturing.<\/p>\n\n  <div class=\"note\">\n    <strong>The catch nobody mentions in the brochure:<\/strong> hPL contains fibrinogen. Add it to medium and you get gel formation unless heparin is present. But heparin is porcine-derived \u2014 which quietly undermines the xeno-free claim that motivated the switch. Fibrinogen-depleted hPL solves this and is the version to specify if xeno-free status has to hold up in a regulatory filing.\n  <\/div>\n\n  <h2>Where human serum is the right answer<\/h2>\n\n  <p class=\"lede\">Human serum sits between the two, and for several applications that is exactly right.<\/p>\n\n  <ul>\n    <li><strong>Prim\u00e4re menschliche Zellen<\/strong> that do not need hPL's growth factor intensity but should not see bovine protein<\/li>\n    <li><strong>PBMC and T-cell work<\/strong> \u2014 <a href=\"https:\/\/seamlessbio.de\/de\/human-serum-typ-ab\/\">Typ AB<\/a> is the established standard, and hPL's proliferative push is not always wanted here<\/li>\n    <li><strong>Physiological modelling<\/strong> \u2014 human serum is a human matrix; hPL is a concentrate and represents no physiological state<\/li>\n    <li><strong>Hormone-sensitive systems<\/strong>, where male-donor serum gives a controlled profile<\/li>\n    <li><strong>Entwicklung diagnostischer Tests<\/strong>, where you need a representative human background rather than growth factors<\/li>\n  <\/ul>\n\n  <p>There is also a regulatory argument: human serum is a well-understood, long-established material with straightforward donor documentation. For some filings that familiarity is worth more than performance.<\/p>\n\n  <h2>What a switch actually costs<\/h2>\n\n  <p class=\"lede\">None of these is a drop-in replacement. Plan for re-qualification, not a purchase order.<\/p>\n\n  <div class=\"tw\">\n    <table>\n      <thead><tr><th>Switch<\/th><th>What to expect<\/th><\/tr><\/thead>\n      <tbody>\n        <tr><td><strong>FBS \u2192 hPL<\/strong><\/td><td>Adaptation over several passages. Concentration usually needs lowering \u2014 hPL at 10 % is often too much. Heparin or fibrinogen-depleted hPL required. Morphology commonly changes.<\/td><\/tr>\n        <tr><td><strong>FBS \u2192 human serum<\/strong><\/td><td>Gentler transition. Growth may slow initially. Off-the-clot Type AB is the closest match to FBS performance.<\/td><\/tr>\n        <tr><td><strong>Human serum \u2192 hPL<\/strong><\/td><td>Usually a performance gain, but the same fibrinogen and concentration considerations apply.<\/td><\/tr>\n        <tr><td><strong>Any switch, clinical process<\/strong><\/td><td>Full comparability exercise: identity, potency, differentiation capacity, karyotype stability. Budget months, not weeks.<\/td><\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <p>We have written up the qualification side separately: <a href=\"https:\/\/seamlessbio.de\/de\/wechsel-des-lieferanten-fur-humanserum\/\">Wechsel des Lieferanten f\u00fcr Humanserum<\/a>.<\/p>\n\n  <h2>A short decision path<\/h2>\n\n  <div class=\"tw\">\n    <table>\n      <thead><tr><th>Your situation<\/th><th>Start with<\/th><\/tr><\/thead>\n      <tbody>\n        <tr><td>MSC expansion for a clinical or ATMP process<\/td><td>hPL, fibrinogen-depleted<\/td><\/tr>\n        <tr><td>MSC expansion, research only<\/td><td>hPL or FBS \u2014 hPL if you plan to go clinical later<\/td><\/tr>\n        <tr><td>T-cell or CAR-T expansion<\/td><td>Human serum Type AB<\/td><\/tr>\n        <tr><td>PBMC and immunology<\/td><td>Human serum Type AB<\/td><\/tr>\n        <tr><td>Primary human cells, general<\/td><td>Human serum Type AB, off-the-clot<\/td><\/tr>\n        <tr><td>Established immortalised cell lines<\/td><td>FBS<\/td><\/tr>\n        <tr><td>Diagnostic assay matrix<\/td><td>Pooled human serum<\/td><\/tr>\n        <tr><td>Xeno-free requirement in a filing<\/td><td>hPL heparin-free, or human serum<\/td><\/tr>\n      <\/tbody>\n    <\/table>\n  <\/div>\n\n  <p>Serum-free is the fourth option and a different discussion \u2014 see our <a href=\"https:\/\/seamlessbio.de\/de\/anpassung-an-die-serumfreie-zellkultur\/\">serum-free adaptation guide<\/a> and the <a href=\"https:\/\/seamlessbio.de\/de\/serumersatz\/\">Serumersatz<\/a> range.<\/p>\n\n  <div class=\"faq\">\n    <h2>H\u00e4ufig gestellte Fragen<\/h2>\n\n    <p class=\"fq\">Is hPL always better than FBS?<\/p>\n    <p>For mesenchymal stromal cells, generally yes on proliferation. For other cell types the picture is mixed \u2014 some lines still perform best in FBS, and hPL's high growth factor content can push cells toward phenotypes you did not intend. Test before committing.<\/p>\n\n    <p class=\"fq\">Why does hPL cause gel formation?<\/p>\n    <p>It contains fibrinogen from the platelet concentrate. In medium containing calcium, fibrinogen can convert to fibrin. Heparin prevents this, or you use fibrinogen-depleted hPL and avoid the problem entirely.<\/p>\n\n    <p class=\"fq\">Is hPL genuinely xeno-free?<\/p>\n    <p>The lysate itself is. If your protocol adds porcine heparin to control fibrinogen, the overall process is not. Fibrinogen-depleted, heparin-free hPL is the version to specify when the claim has to hold.<\/p>\n\n    <p class=\"fq\">Can I use human serum instead of hPL for MSC?<\/p>\n    <p>Yes, and it was the standard before hPL became established. Expect slower proliferation and fewer doublings before senescence. If your process tolerates that, human serum has the simpler documentation trail.<\/p>\n\n    <p class=\"fq\">What concentration of hPL should I use?<\/p>\n    <p>Usually lower than the FBS concentration you are replacing \u2014 often around 5 %, sometimes less. Start with a small concentration series rather than a direct one-to-one substitution; more is not better with hPL.<\/p>\n\n    <p class=\"fq\">Does FBS still have a place?<\/p>\n    <p>Yes \u2014 for established cell lines, routine research and any application with no clinical trajectory. The arguments against it are about origin and regulation, not culture performance.<\/p>\n\n    <p class=\"fq\">How does batch variability compare?<\/p>\n    <p>FBS varies with herd, region and season. Human serum varies by donor. hPL is typically produced from large donor pools, which averages out individual variation \u2014 one of the underrated reasons it suits manufacturing.<\/p>\n\n    <p class=\"fq\">Can I get samples of all three?<\/p>\n    <p>Yes. For a switch decision, running the three in parallel against your own cells is the only assessment that means anything.<\/p>\n  <\/div>\n\n  <div class=\"rel\">\n    <h2>Related<\/h2>\n    <div class=\"rg\">\n      <a href=\"https:\/\/seamlessbio.de\/de\/human-serum-guide\/\">Human Serum Selection Guide \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/human-serum-off-the-clot-vs-plasma-derived\/\">Off-the-Clot vs. Plasma-Derived \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/menschliches-thrombozytenlysat\/\">Human Platelet Lysate \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/human-serum-typ-ab\/\">Menschliches Serum Typ AB \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/fotales-rinderserum\/\">F\u00f6tales Rinderserum \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/fbs-im-vergleich-zu-humanserum\/\">FBS vs. Human Serum \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/biopharma-atmp\/\">Cell Therapy &amp; ATMP \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/anpassung-an-die-serumfreie-zellkultur\/\">Serum-Free Adaptation \u2192<\/a>\n      <a href=\"https:\/\/seamlessbio.de\/de\/wechsel-des-lieferanten-fur-humanserum\/\">Switching Supplier \u2192<\/a>\n    <\/div>\n  <\/div>\n\n  <div class=\"cta\">\n    <h2>Run all three against your own cells<\/h2>\n    <p>We supply FBS, human serum and hPL \u2014 so we have no reason to talk you into one of them. Tell us the cell type and where the process is heading, and we will send samples of the variants worth testing.<\/p>\n    <a class=\"btn\" href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\">Request samples<\/a>\n  <\/div>\n\n<\/div>\t\t\t\t<\/div>\n\t\t\n<\/div>\n\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Home\/ Resources\/ Human Serum vs. hPL vs. FBS Cell Culture Supplements \u00b7 MSC &amp; ATMP Human Serum vs. hPL vs. FBS \u2014 Which Supplement for MSC and ATMP Manufacturing? Three [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_eb_attr":"","footnotes":""},"class_list":["post-2784","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Human Serum vs. hPL vs. FBS for MSC and ATMP | SeamlessBio<\/title>\n<meta name=\"description\" content=\"Which supplement for MSC expansion? Growth factors, xeno-free status, regulatory acceptance and what a switch really costs in validation time.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/human-serum-vs-hpl-vs-fbs\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guide Human Serum vs. HPL vs. FBS\" \/>\n<meta property=\"og:description\" content=\"Which supplement for MSC expansion? Growth factors, xeno-free status, regulatory acceptance and what a switch really costs in validation time.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/human-serum-vs-hpl-vs-fbs\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-25T22:46:59+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"6\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/\",\"name\":\"Human Serum vs. hPL vs. FBS for MSC and ATMP | SeamlessBio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-07-25T22:46:57+00:00\",\"dateModified\":\"2026-07-25T22:46:59+00:00\",\"description\":\"Which supplement for MSC expansion? Growth factors, xeno-free status, regulatory acceptance and what a switch really costs in validation time.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/seamlessbio.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guide Human Serum vs. HPL vs. FBS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/#local-main-organization-logo\"},\"telephone\":[],\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\",\"Saturday\",\"Sunday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/human-serum-vs-hpl-vs-fbs\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png\",\"width\":309,\"height\":88,\"caption\":\"SeamlessBio\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Human Serum vs. hPL vs. FBS for MSC and ATMP | SeamlessBio","description":"Which supplement for MSC expansion? Growth factors, xeno-free status, regulatory acceptance and what a switch really costs in validation time.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/human-serum-vs-hpl-vs-fbs\/","og_locale":"de_DE","og_type":"article","og_title":"Guide Human Serum vs. HPL vs. FBS","og_description":"Which supplement for MSC expansion? Growth factors, xeno-free status, regulatory acceptance and what a switch really costs in validation time.","og_url":"https:\/\/seamlessbio.de\/de\/human-serum-vs-hpl-vs-fbs\/","og_site_name":"SeamlessBio","article_modified_time":"2026-07-25T22:46:59+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"6\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/","url":"https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/","name":"Human Serum vs. hPL vs. FBS for MSC and ATMP | SeamlessBio","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-07-25T22:46:57+00:00","dateModified":"2026-07-25T22:46:59+00:00","description":"Which supplement for MSC expansion? Growth factors, xeno-free status, regulatory acceptance and what a switch really costs in validation time.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/seamlessbio.de\/"},{"@type":"ListItem","position":2,"name":"Guide Human Serum vs. HPL vs. FBS"}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/#local-main-organization-logo"},"telephone":[],"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday","Saturday","Sunday"],"opens":"09:00","closes":"17:00"}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/human-serum-vs-hpl-vs-fbs\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/cropped-cropped-cropped-\u0438\u0437\u043e\u0431\u0440\u0430\u0436\u0435\u043d\u0438\u0435_2026-04-26_165903047.png","width":309,"height":88,"caption":"SeamlessBio"}]}},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=2784"}],"version-history":[{"count":5,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2784\/revisions"}],"predecessor-version":[{"id":2789,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/pages\/2784\/revisions\/2789"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=2784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}